Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib vs Prednisone in Metastatic Castration-resistant Prostate Cancer After Docetaxel and Abiraterone or Enzalutamide
2012-001834-33Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Overall survival. Started Jun 2012; status: completed.
02
Drugs
cabozantinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2012-001834-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001834-33.